Abstract: A method of treating or improving neurological function in a human subject includes identifying a human subject diagnosed with at least one of post-CNS trauma, post-concussion syndrome, a chronic refractive epileptic encephalopathic condition, autism spectrum condition, cerebral palsy; or ischemic long term treatment for remote ischemic or traumatic brain injury; and administering to the human subject a composition comprising a pharmaceutically effective dose of filgrastim.

Abstract: A method for treating warts includes administering to a patient with warts a composition having an autologous, matched allogenic, donor tissue source of mixed, hematological, pleuripotent, ISPC derived or harvested or induced mesenchymal type stem cells and/or filgrastim, derivatives, bioequivalents, and pharmaceutically effective salts thereof. Patients include both non-chemotherapy or non-immunosuppressed patients, as well as chemotherapy or immunosupressed patients with warts of non-responsive cutaneous type. The treatment leads to resolution of warts and/or a change in their response to laser therapy or standard treatments previously shown not to be effective.

Abstract: A method of treating or improving neurological function in a human subject includes identifying a human subject diagnosed with at least one of post-CNS trauma, post-concussion syndrome, a chronic refractive epileptic encephalopathic condition, autism spectrum condition, cerebral palsy; or ischemic long term treatment for remote ischemic or traumatic brain injury; and administering to the human subject a composition comprising a pharmaceutically effective dose of filgrastim.

Abstract: A method for treating an autism spectrum condition includes administering an effective dose of a TNF-? inhibiting agent to a person having an autism spectrum condition or pervasive development disorder and at least one of elevated TNF-? in the cerebrospinal fluid or elevated TNF-? in the serum, as compared to normal conditions; and lowering at least one of the elevated TNF-? in the cerebrospinal fluid or elevated TNF-? in the serum. A TNF-? inhibiting agent includes at least one of Lenalinomide; Thalidomide; L-Carnosine; Infliximab; Etanercept; a stem cell preparation; derivatives thereof, isomers thereof, or pharmaceutically acceptable salts thereof.

Abstract: A method for treating an autism spectrum condition includes administering an effective dose of a TNF-? inhibiting agent to a person having an autism spectrum condition or pervasive development disorder and at least one of elevated TNF-? in the cerebrospinal fluid or elevated TNF-? in the serum, as compared to normal conditions; and lowering at least one of the elevated TNF-? in the cerebrospinal fluid or elevated TNF-? in the serum. A TNF-? inhibiting agent includes at least one of Lenalinomide; Thalidomide; L-Carnosine; Infliximab; Etanercept; a stem cell preparation; derivatives thereof, isomers thereof, or pharmaceutically acceptable salts thereof.

Abstract: A method for treating an autism spectrum condition includes administering an effective dose of a TNF-? inhibiting agent to a person having an autism spectrum condition or pervasive development disorder and at least one of elevated TNF-? in the cerebrospinal fluid or elevated TNF-? in the serum, as compared to normal conditions; and lowering at least one of the elevated TNF-? in the cerebrospinal fluid or elevated TNF-? in the serum. A TNF-? inhibiting agent includes at least one of Lenalinomide; Thalidomide; L-Carnosine; Infliximab; Etanercept; a stem cell preparation; derivatives thereof, isomers thereof, or pharmaceutically acceptable salts thereof.

Abstract: The present invention relates to materials and methods for treating neurological diseases and disorders including but not limited to epilepsy and autism, as well as general cognitive problems.

Abstract: A method for treating an autism spectrum condition includes administering an effective dose of a TNF-? inhibiting agent to a person having an autism spectrum condition or pervasive development disorder and at least one of elevated TNF-? in the cerebrospinal fluid or elevated TNF-? in the serum, as compared to normal conditions; and lowering at least one of the elevated TNF-? in the cerebrospinal fluid or elevated TNF-? in the serum. A TNF-? inhibiting agent includes at least one of Lenalinomide; Thalidomide; L-Carnosine; Infliximab; Etanercept; a stem cell preparation; derivatives thereof, isomers thereof, or pharmaceutically acceptable salts thereof.

Abstract: A method for diagnosing a pervasive developmental disorder, such as autism, comprising obtaining a sample of cerebrospinal fluid from a subject; obtaining a sample of serum from a subject; testing the cerebrospinal fluid of the subject for a concentration of TNF-?; testing the serum of the subject for a concentration of TNF-?; and positively diagnosing a pervasive developmental disorder when the concentration ratio of TNF-? in the cerebrospinal fluid of the subject to TNF-? in the serum of the subject exceeds approximately 2:1 over normal control concentrations.

Abstract: A method for diagnosing a pervasive developmental disorder, such as autism, comprising obtaining a sample of cerebrospinal fluid from a subject; obtaining a sample of serum from a subject; testing the cerebrospinal fluid of the subject for a concentration of TNF-?; testing the serum of the subject for a concentration of TNF-?; and positively diagnosing a pervasive developmental disorder when the concentration ratio of TNF-? in the cerebrospinal fluid of the subject to TNF-? in the serum of the subject exceeds approximately 2:1 over normal control concentrations.

Abstract: A method for treating autism comprising the step of administering an effective amount of Memantine and dextromethorphan or pharmaceutically acceptable derivatives and/or salts thereof.

Abstract: The present invention relates to materials and methods for treating neurological diseases and disorders including but not limited to epilepsy and autism, as well as general cognitive problems.

Abstract: A method for treating autism comprising the step of administering an effective amount of a medicament characterized as a NMDA-receptor antagonist or a pharmaceutically acceptable salt thereof.